Tumour entities and staging for patients with confirmed cancer (n=555)
| Patients with cancer (n=555) | |
|---|---|
| Tumour entity | |
| Lung cancer, n (%) | 61 (11.0%) |
| Breast cancer, n (%) | 146 (26.3%) |
| Brain tumour, n (%) | 23 (4.1%) |
| ENT tumour, n (%) | 33 (5.9%) |
| Gastrointestinal tumours, n (%) | 67 (12.1%) |
| Myelodysplastic malignancies, n (%) | 68 (12.3%) |
| Myeloproliferative neoplasias, n (%) | 99 (17.8%) |
| Oesophageal cancer, n (%) | 11 (2.0%) |
| Testicular cancer, n (%) | 2 (0.4%) |
| Neuroendocrine tumour, n (%) | 11 (2.0%) |
| Sarcoma, n (%) | 9 (1.6%) |
| Mesothelioma, n (%) | 3 (0.6%) |
| Prostate cancer, n (%) | 2 (0.4%) |
| Renal cell carcinoma, n (%) | 4 (0.7%) |
| Thymoma, n (%) | 1 (0.2%) |
| Skin cancer, n (%) | 2 (0.4%) |
| Urogenital tumours, n (%) | 2 (0.4%) |
| Oral cancer, n (%) | 1 (0.2%) |
| Other, n (%) | 10 (1.8%) |
| Tumour stage | |
| Stage 1, n (%) | 93 (16.7%) |
| Stage 2, n (%) | 49 (8.8%) |
| Stage 3, n (%) | 108 (19.5%) |
| Stage 4, n (%) | 177 (31.9%) |
| No staging, n (%) | 128 (23.1%) |
Counts are given as numbers and percentages.
Myelodysplastic malignancies: haematological malignancies with abnormal differentiation of myeloid or lymphoid cell lines (eg, AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; lymphomas, multiple myeloma); myeloproliferative neoplasias: haematological neoplasias with normal cell differentiation (eg, essential thrombocytosis, polycythaemia vera, myelofibrosis).
ENT, ear, nose, throat.